What is ABVC's current stock price?

ABVC (ABVC BioPharma, Inc.) is currently trading at $1.14 with a market cap of $16.5M.

What sector is ABVC BioPharma, Inc. in?

ABVC BioPharma, Inc. (ABVC) operates in the Healthcare sector, specifically in the Biotechnology industry.

InvestLog

ABVC ABVC BioPharma, Inc.

Healthcare

$1.14+1.45%ClosedMarket Cap: $16.5M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

2.69

P/S

-20.75

EV/EBITDA

-2.10

DCF Value

$-0.12

FCF Yield

-20.2%

Div Yield

0.0%

Margins & Returns

Gross Margin

111.6%

Operating Margin

1108.9%

Net Margin

1183.8%

ROE

-92.0%

ROA

-47.8%

ROIC

-56.7%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-1.6M	$—
Q4 null	$-796.0K	$-3.6M	$—
FY null	$0.00	$-7.9M	$—
Q3 null	$0.00	$-2.0M	$—

Analyst Ratings

View All

Consensus

Hold

Target (Consensus)

$—

Target (Median)

$—

Target Range

$— - $—

0 Strong Buy0 Buy1 Hold0 Sell0 Strong Sell

Trading Activity

Insider Trades

View All

Jiang Shulingdirector, 10 percent owner:

SellTue Jul 12

An Chihliangofficer: Chief Financial Officer

SellThu Mar 31

Sakamoto Norimidirector:

SellFri Dec 10

Odaira Yoshinobudirector

SellFri Dec 10

Tseng Shih-Chendirector:

SellMon Nov 15

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

0.42

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.

Peers